Early tests show that VX-01 is safe, with no harmful effects on healthy cells, suggesting that VX-01 could be a promising treatment to help fight mucormycosis in people with weakened immune ...

In it, they discuss the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the fungus to invade human cells and cause mucormycosis. Their findings will ...

Fungal infections in India are rising, with growing resistance to treatment. Learn about common types, causes, drug ...

Future Microbiol. 2014;9(5):683-695. Identification of the causative agent to species level from cultures based on morphological characteristics requires training; strains collected from patients ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Antibody-based therapy is advancing as a potential treatment for mucormycosis, a severe fungal infection with high mortality rates, especially in immunocompromised individuals.

Mucormycosis, a fungus infection caused by Mucorales, has a high mortality rates in those with weakened immune systems and those who have suffered severe trauma, such as burns, blast injuries, or ...